Preimplantation Genetic Testing Market Size, Share, Opportunities, And Trends By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Molecule Polymorphism), By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Application (Aneuploidy, Single Gene Disorders, X-linked Disorders, Others), By End-User (Maternity Clinics, Hospitals, Others), And By Geography - Forecasts From 2024 To 2029

  • Published : Feb 2024
  • Report Code : KSI061616223
  • Pages : 141

The preimplantation genetic testing market is estimated to grow at a CAGR of 10.26% during the forecast period.

Preimplantation genetic diagnosis (PGD) is implemented before IVF workflow. For women who have had several miscarriages and last pregnancy with chromosome abnormality have PGD deployed in IVF cycles. Couples who are at risk of hereditary disorders can benefit from preimplantation genetic testing.

Driving factors for the preimplantation genetic testing market

The major factor influencing the growth of the preimplantation genetic treatment industry is the growing frequency of infertility among individuals and rising genetic problems. Preimplantation genetic testing is growing in demand as it detects defective embryos and has some genetic disorders and other faults that lead to the child being born with health defects. Individuals who have single gene donors, sex-linked genetic disorders, chromosomal problems, or have a history of multiple abortions are increasingly using preimplantation genetic testing methods.

Growing prevalence of neo-natal deaths

Many genetic deformities cause newborn deaths around the globe and hence will propel the growth of the preimplantation genetic treatment market. For instance, according to UNICEF, 6,400 newborns died every day in 2021. Furthermore, there were 18 deaths per thousand live births worldwide making the first month the most dangerous for newborns. Preimplantation genetic diagnosis helps in curbing this issue as it detects defective chromosomes at an early stage and prevents congenital genetic deformities in the fetuses. As the women’s age for childbearing increases so is the use of preimplantation genetic testing.

Rising adoption of polymerase chain reaction

Polymerase chain reaction is anticipated to hold the maximum market share during the forecast period owing to the high market penetration and rising cost-effectiveness with high accuracy of PCR tests are fueling the preimplantation genetic treatment industry share. The polymerase chain reaction increases the chance of detection of any chromosomal abnormalities with a large number of copies of a particular stretch of the genome. This technology is suitable for all types of genetic diagnosis.

Growing prevalence of preimplantation genetic diagnosis

The major factor driving the growth of the preimplantation genetic treatment market is the growing awareness among healthcare professionals and consumers about genetic testing. The rising incidence of single gene disease and translocation cases led to the effective delivery of NGS technology for genetic testing. The preimplantation genetic diagnosis (PGD) services help reduce the incidences of genetic diseases which is done by embryo examination to determine specific gene mutations. The PGS services are also gaining popularity as they are suggested for couples with multiple IVF cycles, advanced age, and recurrent pregnancy loss.

Advancements in medical technologies

The growing demand for improved medical services and increasing income is fueling opportunities for the development of advanced diagnostic and treatment approaches. As the need to prevent physical abnormalities and health problems has increased the preimplantation genetic treatment market has seen growth for early diagnostic approaches. These early diagnostic approaches are being used during genetic invitro fertilization and other artificial insemination procedures. Preimplantation genetic testing methods can detect inherited disorders including congenital hearing loss, cystic fibrosis, and many more.

Adoption of next-generation sequencing technology

Next-generation sequencing drives the preimplantation genetic treatment industry due to its high accuracy, efficiency, and comprehensive genetic information. The next-generation sequencing method provides detailed genetic analysis which results in improved success rates of assisted reproductive techniques. Moreover, the adoption of florescent in-situ hybridization is also significantly impacting the preimplantation genetic treatment market due to the growing need to detect chromosomal abnormalities in embryos before implantation. FISH offers rapid results and screens a limited number of chromosomes at a time.

IVF Prognosis is anticipated to hold a significant market share

Preimplantation genetic testing plays an important role in IVF prognosis as it is necessary to inspect the medical condition of the embryos, thereby contributing to the growth of IVF prognosis. The high demand for invitro fertilization procedures is increasing the demand for preimplantation genetic testing procedures in the market. Additionally, many product launches by major market players are further fueling the preimplantation genetic treatment market growth. Rising infertility and increasing preference for IVF procedures are expected to drive the growth of the preimplantation genetic treatment market during the forecast period.

In Europe, it is projected that the preimplantation genetic testing market will grow steadily. 

The European region is anticipated to secure a sizable preimplantation genetic treatment market share. The regional preimplantation genetic treatment market will be fueled by the increasing prevalence of late pregnancies. Additionally, the growing liberal regulations in various countries in Europe for screening and the presence of leading market players are fueling the regional preimplantation genetic treatment industry. Furthermore, Asia Pacific is anticipated to grow significantly during the forecast period due to advancements in reproductive health. High adoption of IVF and increasing consumer awareness are further fueling the preimplantation genetic treatment market growth.

Market Key Developments

  • In April 2023, The HelpCureHD Foundation and Prelude Network launched the More Than Fertility campaign to increase and educate awareness about IVF with Preimplantation Genetic Testing.
  • In October 2022, Genomic Prediction and HelpCureHD collaborated to help partners with the risk of Huntington's disease screen through preimplantation genetic testing.
  • In October 2022, Ovation Fertility and Genomic Prediction partners to license the LifeView PGT platform.
  • In July 2022, To screen genetic diseases in IVF embryos, GenEmbryomics launched research using genome sequencing tests.

Preimplantation Genetic Testing Market Scope:


Report Metric Details
Growth Rate CAGR of 10.26% from 2022 to 2029
Study Period
2019 to 2029
Historical Data
2019 to 2022
Base Year 2023
Forecast Period 2024 – 2029
Forecast Unit (Value) USD Billion
Segments Covered
  • Technology
  • Procedure Type
  • Application
  • End-User
  • Geography
Companies Covered
  • Milann Fertility Center
  • Pac Genomics
  • Thermo Fisher Scientific
  • Natera
  • Illumina
Regions Covered North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope Free report customization with purchase



  • By Technology
    • Next Generation Sequencing
    • Polymerase Chain Reaction
    • Fluorescent In-Situ Hybridization
    • Comparative Genomic Hybridization
    • Single Molecule Polymorphism
  • By Procedure Type
    • Preimplantation Genetic Screening
    • Preimplantation Genetic Diagnosis
  • By Application
    • Aneuploidy
    • Single Gene Disorders
    • X-linked Disorders
    • Others
  • By End-User
    • Maternity Clinics
    • Hospitals
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others

Frequently Asked Questions (FAQs)

The global preimplantation genetic testing market is estimated to grow at a CAGR of 10.26% during the forecast period.
Prominent key market players in the preimplantation genetic testing market include Milann Fertility Center, Pac Genomics, Thermo Fisher Scientific, Natera, and Illumina, among others.
The preimplantation genetic testing market has been segmented by technology, procedure type, application, end-user, and geography.
The major factor influencing the preimplantation genetic treatment market growth is the growing frequency of infertility among individuals and rising genetic problems.
Europe is expected to hold a significant share of the preimplantation genetic testing market.


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Next Generation Sequencing

5.3. Polymerase Chain Reaction

5.4. Fluorescent In-Situ Hybridization

5.5. Comparative Genomic Hybridization

5.6. Single Molecule Polymorphism


6.1. Introduction

6.2. Preimplantation Genetic Screening

6.3. Preimplantation Genetic Diagnosis


7.1. Introduction

7.2. Aneuploidy

7.3. Single Gene Disorders

7.4. X-linked Disorders

7.5. Others


8.1. Introduction

8.2. Maternity Clinics

8.3. Hospitals

8.4. Others


9.1. Introduction

9.2. North America

9.2.1. United States

9.2.2. Canada

9.2.3. Mexico

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. United Kingdom

9.4.2. Germany

9.4.3. France

9.4.4. Spain

9.4.5. Others

9.5. The Middle East and Africa

9.5.1. Saudi Arabia

9.5.2. UAE

9.5.3. Israel

9.5.4. Others

9.6. Asia Pacific

9.6.1. Japan

9.6.2. China

9.6.3. India

9.6.4. South Korea

9.6.5. Indonesia

9.6.6. Thailand

9.6.7. Others


10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix


11.1. Milann Fertility Center

11.2. Pac Genomics

11.3. Thermo Fisher Scientific

11.4. Natera

11.5. Illumina

11.6. Johns Hopkins Medicine

11.7. NYU Langone Health

11.8. Cloudnine Fertility

11.9. MedGenome

11.10. CNY Fertility

Milann Fertility Center

Pac Genomics

Thermo Fisher Scientific



Johns Hopkins Medicine

NYU Langone Health

Cloudnine Fertility


CNY Fertility